Grants & Programs

News & Resources

The Cancer Immunotherapy Consortium embraces communication and collaboration among its members and among other like-minded associations that strive to bring effective immune-based cancer treatments to more patients.

CIC members contribute to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.

We invite you to browse our library of publications, news releases, and e-newsletters.

Latest News

Page 1 of 3
  • Immudex Takes On International Proficiency Panels

    Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.

    April 23, 2013

  • Community-wide Consensus Process Generates a Framework for Reporting of T-cell Experiments in Clinic

    The Association for Cancer Immunotherapy Immunoguiding Program and the Cancer Immunotherapy Consortium of the Cancer Research Institute today announced a publication discussing the results of a unique collaborative vetting process which has now led to publication guidelines that increase transparency of immune response assessments.

    July 25, 2012

  • Critical Value Demonstrated for Immune Assay Harmonization

    The Association for Cancer Immunotherapy Immunoguiding Program and the Cancer Immunotherapy Consortium of CRI published a joint paper discussing recent results of independent international, cross-laboratory immune assay harmonization studies.

    November 8, 2011

  • Cancer Immunotherapy Consortium Appoints New Leadership

    Drs. James P. Allison, chair of the immunology program at Memorial Sloan-Kettering Cancer Center, and Axel Hoos, medical lead in immunology/oncology at Bristol-Myers Squibb, have been named directors of the CRI Cancer Immunotherapy Consortium (CIC), the premier academic-industry association dedicated to accelerating development of safe and effective cancer immunotherapies to patients.

    November 7, 2011

  • Collaborative Partnership Pioneers Model to Improve Clinical Success of Cancer Immunotherapies

    The Cancer Immunotherapy Consortium of the Cancer Research Institute and the Association for Cancer Immunotherapy have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.

    October 17, 2011

Become a member

Are you interested in becoming part of the Cancer Immunotherapy Consortium?

Join Now

Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at consortium@cancerresearch.org or (212) 688-7515.